Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STXS 
Stereotaxis Inc (STXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: STXS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.76% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 196.94M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 4 | Beta 1.46 | 52 Weeks Range 1.54 - 2.72 | Updated Date 06/30/2025 |
52 Weeks Range 1.54 - 2.72 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -92.19% | Operating Margin (TTM) -79.35% |
Management Effectiveness
Return on Assets (TTM) -34.75% | Return on Equity (TTM) -179.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 197504944 | Price to Sales(TTM) 7.16 |
Enterprise Value 197504944 | Price to Sales(TTM) 7.16 | ||
Enterprise Value to Revenue 7.18 | Enterprise Value to EBITDA -10.06 | Shares Outstanding 86000800 | Shares Floating 58854681 |
Shares Outstanding 86000800 | Shares Floating 58854681 | ||
Percent Insiders 31.6 | Percent Institutions 47.52 |
Analyst Ratings
Rating 2 | Target Price 4.5 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Stereotaxis Inc
Company Overview
History and Background
Stereotaxis Inc. was founded in 2001. It focuses on developing robotic technologies for minimally invasive surgical interventions. Initially focused on cardiac ablation, the company has expanded its technology to other areas.
Core Business Areas
- Robotic Systems: Development, manufacturing, and marketing of robotic systems for minimally invasive surgery, primarily focusing on remote navigation of catheters and other interventional devices.
- Consumables: Sale of disposable devices such as magnetic navigation catheters, guide wires, and other accessories used in conjunction with the robotic systems.
- Services: Providing training, maintenance, and support services for the installed base of robotic systems.
Leadership and Structure
David Fischel serves as Chairman and CEO. The company has a board of directors and a management team overseeing various functions such as research and development, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Genesis RMN System: A robotic magnetic navigation system used primarily for cardiac ablation procedures. It enables physicians to remotely navigate catheters within the heart with precision and control. Market share data is difficult to pinpoint exactly as Stereotaxis is only one piece of the cardiac ablation market. Competitors include Biosense Webster (Johnson & Johnson), Abbott, and Boston Scientific.
- Niobe ES System: An earlier version of the robotic navigation system, still in use at some centers. It also uses magnetic navigation to guide catheters. Market share data is difficult to pinpoint exactly as Stereotaxis is only one piece of the cardiac ablation market. Competitors include Biosense Webster (Johnson & Johnson), Abbott, and Boston Scientific.
- StereoCath Catheters: A range of disposable catheters designed for use with the robotic navigation systems. These are integral to the system's functionality and generate recurring revenue. Market share data is difficult to pinpoint exactly as Stereotaxis is only one piece of the cardiac ablation market. Competitors include Biosense Webster (Johnson & Johnson), Abbott, and Boston Scientific.
Market Dynamics
Industry Overview
The market for minimally invasive surgical technologies is growing, driven by demand for less invasive procedures, improved patient outcomes, and reduced hospital stays. The electrophysiology market, where Stereotaxis primarily operates, is also expanding due to the increasing prevalence of cardiac arrhythmias.
Positioning
Stereotaxis occupies a niche position in the electrophysiology market with its robotic navigation technology. Its competitive advantage lies in the precision and control offered by its systems, potentially leading to improved ablation outcomes. However, the high cost of the system and the need for specialized training can be barriers to adoption.
Total Addressable Market (TAM)
The total addressable market for cardiac ablation and related procedures is estimated to be in the billions of dollars annually. Stereotaxis' positioning within this TAM is focused on centers and physicians willing to invest in advanced technology for improved outcomes.
Upturn SWOT Analysis
Strengths
- Proprietary Robotic Navigation Technology
- Potential for Improved Precision and Control
- Established Base of Installed Systems
- Recurring Revenue from Consumables
Weaknesses
- High System Cost
- Limited Market Penetration
- Dependence on Electrophysiology Market
- Relatively Small Company Size
Opportunities
- Expansion into New Clinical Applications
- Increased Adoption of Minimally Invasive Procedures
- Strategic Partnerships with Medical Device Companies
- Development of Next-Generation Robotic Systems
Threats
- Competition from Established Medical Device Companies
- Technological Advancements by Competitors
- Changes in Healthcare Reimbursement Policies
- Economic Downturn Impacting Hospital Capital Spending
Competitors and Market Share
Key Competitors
- JNJ
- ABT
- BSX
Competitive Landscape
Stereotaxis competes with larger, more established medical device companies. Its competitive advantage lies in its proprietary robotic navigation technology, but it faces challenges in terms of market penetration and financial resources.
Growth Trajectory and Initiatives
Historical Growth: Stereotaxis' historical growth has been characterized by periods of rapid revenue growth followed by periods of slower growth or decline. This is largely influenced by the capital equipment sales cycle.
Future Projections: Analyst projections for Stereotaxis' future growth vary, but generally anticipate continued expansion of the electrophysiology market and increased adoption of robotic navigation technology. Revenue growth is the key.
Recent Initiatives: Recent strategic initiatives may include new product launches, partnerships, and geographic expansion.
Summary
Stereotaxis is a company with promising robotic technology in the electrophysiology field. Its strengths include its proprietary technology and installed base, but its weaknesses include high system costs and limited market penetration. The company must focus on growing revenue, expanding into new clinical applications, and strategically managing its expenses to become a stronger player in the space. Market penetration is key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Stereotaxis Inc. Investor Relations
- Company Filings (SEC)
- Industry Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available information. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stereotaxis Inc
Exchange NYSE MKT | Headquaters Saint Louis, MO, United States | ||
IPO Launch date 2004-08-12 | CEO & Chairman Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 139 | Website https://www.stereotaxis.com |
Full time employees 139 | Website https://www.stereotaxis.com | ||
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is designed to enhance the accessibility of RMN by eliminating the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; V-CAS; and MAGiC catheter for cardiac ablation procedures. Further, it provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.